It is, therefore, tempting to speculate that chemical inhibitorsof IPMK may be capable of uniquely targeting PTEN-negative glioblastoma,particularly in patients who have not responded well to therapiesthat decrease AKT phosphorylation. This evidence concerns the gene PTEN and glioblastoma.